Clinical data | |
---|---|
Trade names | Adequan |
AHFS/Drugs.com | Veterinary Use |
License data | |
Routes of administration | Usually IM or IA |
ATCvet code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 30–40% |
Metabolism | Renal |
Onset of action | 48 hours for peak levels in joints (IM) |
Duration of action | 96 hours (IM) |
Excretion | Urine |
Identifiers | |
UNII | |
Chemical and physical data | |
Molar mass | 3,000–15,000 Da |
Polysulfated glycosaminoglycan (PSGAG), sold under the brand name Adequan, is an injectable drug for dogs and horses that is used to alleviate the limpness, pain, and lowered range of motion caused by arthritis.[2] It is made of repeat disaccharide units (comprising hexosamine and hexuronic acid), and is similar to glycosaminoglycans already present in the cartilage; PSGAG thus easily integrates itself there.[3][4] In vitro studies have shown it to inhibit the enzymes that degrade cartilage and bone, as well as suppress inflammation and stimulate the synthesis of replacement cartilage. While it can cause an increased risk of bleeding, it is relatively safe and has a high LD50. PSGAG is one of the most widely prescribed joint treatments for horses.[5]
While it is widely used, some studies still show conflicting results in terms of efficacy, causing some to claim that PSGAG is not solely responsible for the significant mitigation of arthritis seen in success cases.[6]
plumb
was invoked but never defined (see the help page).